The new £6 million investment will help to further the development of Mirada’s state of the art software algorithms and imaging applications.
News
Sanofi ends option phase of rare disease alliance with Alnylam
Through the agreement Alnylam will advance an additional investigational asset in an undisclosed rare genetic disease.
Categories refined for the 2019 PharmaTimes Sales Awards
The categories for the 2019 PharmaTimes Sales Awards have been refined to greater reflect current trends and changes in the healthcare sales sector.
NICE appraisal for BMS kidney cancer immunotherapy combination
The Institute gave a positive FAD to the Opdivo and Yervoy combination in renal cell carcinoma, approving funding via the Cancer Drugs Fund.
AZ’s Fasenra shows promise in hypereosinophilic syndrome
The drug is AstraZeneca’s first respiratory biologic.
EU approves new dosing schedule for MSD’s Keytruda
The less frequent dosing gives both patients and oncologists more flexibility, helping to free up hospitals.
Myriad, AstraZeneca and MSD expand collaboration
The expansion will use BRACAnalysis CDx to identify germline BRCA mutations.
HPV vaccine to thank for 89% decline in cervical cancer
The authors of the study also highlighted a “herd immunity” benefit, as a drop in disease among unvaccinated women was observed.
Brexit will have ‘minimal’ effect on R&D in UK, says expert
The NIHR’s Dr Jonathan Sheffield gave a positive outlook on UK R&D post-Brexit at the ‘Brexit: What’s Next for Pharma?’ PING conference.
Big Pharma come together for better drug side effect detection
The group will consist of pharma giants like Pfizer, Celgene, Roche and BMS among others.
EMA grants PRIME designation to Janssen’s investigational CAR-T therapy
Based on a study that found 88% overall response rate in advanced relapsed or refractory multiple myeloma.
Boots introduces new at-home health checks
The tests include vitamin D, cholesterol, diabetes, and iron deficiency among others.
FDA gives Fast Track Designation to tebentafusp
The drug has already been granted orphan drug designation for melanoma by the FDA.
Finalists announced for the 2019 PharmaTimes Clinical Researcher of the Year – The Americas competition!
The judging panels have analysed all of the entries for this year’s competition and have decided on the individuals and teams who will be progressing to our live finals day in May.
Lyrica reclassified after being linked to 33 deaths
The drug was linked to 33 deaths in in Northern Ireland in 2018, a jump from just eight in 2017.
